Rheumatology International

, Volume 3, Issue 1, pp 19–21 | Cite as

Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population

  • L. J. Catoggio
  • R. P. Skinner
  • P. J. Maddison


To determine the clinical significance of anticentromere (ACA) and anti Scl-70 antibodies in an English population with connective tissue diseases, we examined the sera of 150 patients, including 40 with systemic sclerosis (SS), who were prospectively studied on the same clinical protocol in our connective tissue disease clinic.

ACA was present in 44% of the CREST patients as opposed to only 12% of those with SS and diffuse skin involvement. Only two patients without SS had ACA. Anti Scl-70 was detected in 20% of the patients with SS and only two of those with other connective tissue diseases.

We confirmed the specificity of these antibodies for SS. Either anti Scl-70 or ACA was present in half the patients with SS and their presence may represent a useful aid to diagnosis of this disease in patients presenting with Raynaud's phenomenon or an undifferentiated connective tissue disease.

While less than half the CREST patients had ACA, this antibody appears to identify those patients within the CREST variant with skin involvement confined to sclerodactyly as opposed to those with acrosclerosis. These patients, however, did not differ in the degree of visceral involvement.

Key words

Scleroderma Systemic sclerosis Anticentromere antibody Anti Scl-70 antibody Raynaud's phenomenon 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Douvas A, Achten A, Tan EM (1979) Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 254:10514–10522Google Scholar
  2. 2.
    Moroi Y, Peebles C, Fritzler M, Steigerwald J, Tan E (1980) Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 77:1627–1631Google Scholar
  3. 3.
    Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler M, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis Rheum 23:617–625Google Scholar
  4. 4.
    Fritzler MJ, Kinsella TD, Garbutt E (1980) The CREST syndrome; a distinct serological entity with anticentromere antibodies. Am J Med 69:520–526Google Scholar
  5. 5.
    Bernstein RM, Steigerwald JC, Tan EM (1982) Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol 48:43–51Google Scholar
  6. 6.
    Catoggio LJ, Bernstein RM, Black CM, Hughes GRV, Maddison PJ (1982) Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis (in press)Google Scholar
  7. 7.
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590Google Scholar
  8. 8.
    Cohen AS, Reynolds WE, Franklin EC, Kulka JP, Ropes MW, Shulman LE, Wallace SL (1971) Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 21:643–648Google Scholar
  9. 9.
    American Rheumatism Association criteria for the diagnosis and classification of rheumatic diseases (1973) Primer on rheumatic diseases. JAMA 224 [Suppl]:137–138Google Scholar
  10. 10.
    Clark GM, Reichlin M, Tomasi TB (1969) Characterisation of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythematosus. J Immunol 102:117–122Google Scholar
  11. 11.
    Mattioli M, Reichlin M (1971) Characterisation of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera. J Immunol 107:1281–1290Google Scholar
  12. 12.
    Meyer O, Borda-Oriarte O, Haim T, Ryckewaert A (1982) A profile of antinuclear antibodies in 50 cases of scleroderma. Clin Rheumatol 1:64 (Abstr)Google Scholar
  13. 13.
    Black CM, Maddison PJ, Jayson MIV, Batchelor JR, Walsh KI, Bernstein RM, Catoggio LJ, Holland CD, Hughes GRV (1982) HLA antigens and systemic sclerosis. Arthritis Rheum (in press)Google Scholar
  14. 14.
    Rodnan GP, Jablonska S, Medsger TA (1979) Classification and nomenclature of progressive systemic sclerosis. Clin Rheum Dis 5:5–14Google Scholar
  15. 15.
    Barnett AJ (1974) Scleroderma: progressive systemic sclerosis. Thomas, Springfield, Massachusetts, USAGoogle Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • L. J. Catoggio
    • 1
  • R. P. Skinner
    • 1
  • P. J. Maddison
    • 1
  1. 1.Royal National Hospital for Rheumatic DiseasesBathUK

Personalised recommendations